A second phase Ib clinical trial in patients with paroxysmal nocturnal hemoglobinuria (PNH) to assess the safety, preliminary efficacy and pharmacokinetics of subcutaneously administered APL-2 alone or in combination with eculizumab

Trial Profile

A second phase Ib clinical trial in patients with paroxysmal nocturnal hemoglobinuria (PNH) to assess the safety, preliminary efficacy and pharmacokinetics of subcutaneously administered APL-2 alone or in combination with eculizumab

Recruiting
Phase of Trial: Phase I

Latest Information Update: 21 Nov 2016

At a glance

  • Drugs APL 2 (Primary) ; Eculizumab
  • Indications Paroxysmal nocturnal haemoglobinuria
  • Focus Adverse reactions
  • Most Recent Events

    • 21 Nov 2016 Data from this and another phase Ib trial will be presented at the International PNH Interest Group (IPIG) Annual Scientific Assembly 2016, according to an Apellis Pharmaceuticals media release.
    • 28 Jun 2016 New trial record
    • 23 Jun 2016 Data from this trial are expected to be presented at the American Society of Hematology (ASH) annual meeting in December 2016, according to an Apellis media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top